theprior
17 Oct 2019
Interesting RNS The fact they haven’t got the capacity to meet demand but soon will have is good news and an a viable position to be in. Not surprised about the City reaction because they hate poor numbers and delayed revenue. Anyhow, I topped up on this mornings drop, just watch it rocket when additional production comes on stream
Average_Dave
17 Oct 2019
Interesting RNS Revenue will be less than expected because demand is too high. Who writes these RNSs? A_D
theprior
13 Nov 2018
Pan European distribution agreement Another significant milestone outlined in today’s RNS. I suggest that break even, indeed, profitability, is approaching more quickly than anticipated by many. TP
theprior
03 Sep 2018
Half year results Stunning set of results announced this morning with BE targeted for 2020. The momentum being generated here suggests this may be earlier than that! Well done guys. TP
theprior
25 Jun 2018
CellRight Comes to UK as TRX sign agreement with Pennine Healthcare Nice to see the UK health sector starting to benefit from TRX’s US expansion TP
theprior
02 May 2018
Further commercial agreement RNS today.TP
theprior
24 Apr 2018
Re: Recent developments Manufacturing of DermaPure established in CellRight facility ....see RNS. Perhaps profitability is nearer than you thinkTP
theprior
20 Apr 2018
Re: Recent developments Woodford now 26%TP
theprior
08 Apr 2018
Recent developments Two RNSs have been issued recently... Finals on 26/03 and Hardman Research paper 5/04.Both make interesting reading and indicate that the company is making better progress than they indicated a year or so ago. Absorption of CellRight and overall sales performance is going well and projections to 2020 show good progress to break even.And thereafter profitability.Good recovery from here expected invho.TP
swisspaul
22 Feb 2018
SOUND FAMILIAR? From Mr C on Lemon fool:Sinclair Pharma (SPH) drops US distributor for Silhouette InstaLift end March, by mutual agreement. "Sinclair will pay to Thermi a one-off, undisclosed payment for the early termination and will regain the full US distribution rights for the Products." Why the payment if the termination is mutual? "Advanced discussions with potential US partners are ongoing and we expect to enter into an alternative arrangement effective from 1 April".SPH: Price=22. Cap=111m. F/C for current FY*: EPS= -1.31, Prospective PE= -16.8, Revenue=NA. Sinclair Pharma is a specialty pharmaceutical company focused on Dermatology, in particular - Aesthetics, Wound care, and Skin care.How is the U side of the business?
theprior
18 Jan 2018
What are the chances... ...of an update ?Last meaningful informative operational news were the unaudited Interims back in September, last year !Who is the new CFO? how is the assimilation of Cellright going ? How’s the revenue growing ? Any update on when thecompany might become profitable?Come on guys, spill the beans!!TP
theprior
29 Dec 2017
Re: The patient Rising sp continues apace. +4% so far today.Happy new year !we’ll have to wait till next year to see what’s causing this renewed interest.But, hey, that’s only next week 
))
theprior
21 Dec 2017
Re: The patient Positively glowing now almost +50% from its recent low !
theprior
19 Dec 2017
The patient Seems to be showing slight signs of recovery. Definitely oversold ! TP
waytogo333
08 Dec 2017
I used to have.... ....great hope for this company. Problem is, there's been so much delay in improving the financials and now losing the CEO and CFO without ANY explanation. Frankly, it takes the p***.Now approaching the scenario of 'might as well hang on to the shares to see where it goes', rather than sell at a big loss.Disappointed...
